Original article on AP News
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse events — QR-421a is the second ophthalmology program where clinical activity was predicted by translational models, further validating the platform — COVID-19 pandemic expected to impact timelines for the pipeline — ProQR anticipates its cash runway will fund operations into H2 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., Read
Original text here
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Read
This article aims to collect all the cures for retinitis pigmentosa found on the internet in a single list.
A way to do you a favor and avoid browsing through a myriad of websites. Read
Do you really believe they will find a cure for this damn disease (RP)?
This is the question I wrote on a well-known Facebook group that brings together patients with Retinitis Rigmentosa or Usher Syndrome and their family members. Read